

Flutiform[®] for the treatment of asthma in adults and children over 12 years

NHS Devon

Commissioning policy

The routine commissioning of Flutiform[®] is not accepted in Devon for the treatment of asthma in adults and children over 12 years. The Formulary Interface Group should not include this in locally defined treatment recommendations.

Rationale for the decision

Combination products of inhaled corticosteroid with long-acting β -agonists (ICS/LABA) are available in a range of formulations that are well established in clinical practice. A clinical advantage of Flutiform over existing products with respect to lung function or symptoms of asthma has not been demonstrated. The licensed indications for Flutiform[®] are more restricted than in other products. It is considered that the cost advantages of Flutiform[®] over existing products across the range of doses are not substantial enough to warrant its adoption.

Guidance notes on exceptionality

This general policy does not replace clinical judgement on the appropriate treatment of an individual patient.

Date of publication:	Version:
22.08.2013	Policy agreed by Northern, Eastern and Western Devon CCG and South Devon and Torbay CCG
	Policy adopted by NHS Devon CCG on 01.04.2019
	Policy adopted by NHS Devon ICB on 01.07.2022